On 2 April 2025 NICE approved brentuxtimab vedotin for new diagnosed patients with stage 3 or 4 Hodgkin lymphoma. Brentuximab will be given in combination with 3 chemotherapy drugs – doxorubicin, dacarbazine and vinblastine.
This is excellent news and another treatment option for patients with advanced Hodgkin lymphoma.